awmsg logo



alogliptin (Vipidia®)


Reference No. 857

Publication date:
31/10/2014


Appraisal information

alogliptin (Vipidia®) 6.25 mg film-coated tablet
alogliptin (Vipidia®) 12.5 mg film-coated tablet
alogliptin (Vipidia®) 25 mg film-coated tablet


Company: Takeda UK Ltd
BNF category: Endocrine system
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2914
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Alogliptin (Vipidia®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin (Vipidia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control: • In combination with metformin (dual therapy), when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulphonylurea is inappropriate; • In combination with a sulphonylurea (dual therapy), when a sulphonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate. Alogliptin (Vipidia®) is not recommended for use within NHS Wales outside of these circumstances.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download